16x faster monitoring oversight for a Phase 1 oncology sponsor

Executive summary

Challenge: A Phase 1 oncology sponsor running a global, multi-site study was missing compliance findings, with monitoring gaps only surfacing at audit.

Solution: The Phases monitoring agent analyzed 130+ monitoring visit reports against the protocol, CMP, and PD log without requiring weeks of configuration.

Results: The sponsor team can now review each monitoring report in under 5 minutes, saving 94% of report review time and cost. Every deviation is flagged and stored as a fully citable audit trail, ready for FDA inspection.

Challenge

Monitoring visit reports are one of the most detailed artifacts created during a trial, yet for most teams, reviewing all of them is simply not feasible. CRAs and CTMs are stretched across site management, query resolution, regulatory obligations and more. Analyzing every report in full against the protocol, CMP and PD log requires hours of meticulous review and, in turn, gets deprioritized.

For this sponsor, the consequences were tangible: CRAs and study teams were consistently missing findings that only surfaced during audits. This late discovery has the potential to turn a manageable finding into a formal audit finding or timeline delay.

The cost of this oversight gap is not immediately visible. Unreported protocol deviations sit undetected. Documentation gaps accumulate. Site and monitoring trends that would flag an issue early only emerge in aggregate. Left unaddressed, these issues delay timelines, inflate costs, and put approval-grade data at risk.

Solution

The sponsor provided 130+ monitoring visit reports along with the study protocol, clinical monitoring plan and the PD log. The Phases monitoring agent analyzed all reports, checking each one against protocol requirements and CMP obligations. Every finding was categorized by type and severity and cited with direct references to the relevant sections of the source documents, so the sponsor team could verify each one independently in minutes.

To establish a credible performance baseline and validate AI performance, a human reviewer with 25 years of clinical operations experience reviewed a subset of the reports, providing a direct comparison on identical source material.

Results

Phases reviewed the full set of monitoring visit reports against the protocol and clinical monitoring plan, finding that the existing review process had left significant compliance risk unaddressed. The agent identified 13 protocol deviations in the monitoring visit reports that had never been entered into the study PD log, meaning the sponsor had no official record of them. A further 8 had not been caught by any prior review. Left unresolved, findings like these accumulate into audit risk: an FDA inspection or internal QA review surfacing deviations that should have been caught and closed months earlier can be extremely damaging to trial timelines, budget, and submission viability.

Beyond deviations, Phases surfaced 313 report quality issues against the CMP and protocol requirements, and identified 27 performance trends across the report set. For the first time, the sponsor team had a complete and current picture of what was actually happening across their study.

Impact

Before Phases, achieving 100% monitoring visit report oversight manually was cost-prohibitive, costing an estimated $90,000 per year on this study.

Phases delivered 100% report coverage at much higher review quality, while saving 94% of review time and cost. The sponsor team can now review each monitoring report in under 5 minutes, instead of roughly 1.5 hours when done manually. Across the 130+ provided reports, this translated to 194 hours of manual review time saved, equivalent to about 5 weeks of work for someone on the team.

This deployment was a structural shift in what monitoring oversight looks like for the sponsor team. Teams that previously had to choose between oversight coverage and cost can now have both. Every report is analyzed, every deviation is flagged, and the entire review is stored as a fully citable audit trail, ready for FDA inspection at any time.